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ABSTRACT/SUMMARY   47 
 48 
Background: Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, 49 
liver enzymes and insulin resistance in murine models of fatty liver disease. They are 50 
licensed for type 2 diabetes, but their efficacy in patients with non-alcoholic 51 
steatohepatitis is unknown. The aim of the study was to assess the efficacy and 52 
safety of the long-acting GLP-1 analogue, liraglutide, in patients with non-alcoholic 53 
steatohepatitis. 54 
 55 
Methods: This multicentre, double-blinded, randomised, placebo-controlled phase II 56 
trial was conducted in the UK to assess 48-weeks treatment with once-daily, 57 
subcutaneous injections of 1.8mg liraglutide or liraglutide-placebo in overweight 58 
patients with non-alcoholic steatohepatitis. Patients were randomly assigned 1:1 59 
using a computer-generated, centrally administered procedure, stratified by trial 60 
centre and diabetes status. The trial was designed using A’Herns single arm method 61 
requiring 8/21 (38%) successes in the liraglutide arm. It incorporated a concurrently 62 
randomised placebo group to provide an unbiased assessment of outcome for this 63 
patient population. The primary outcome measure was improvement in liver 64 
histology, defined as ‘resolution of definite NASH’ with no worsening in fibrosis from 65 
baseline to end-of-treatment, as assessed centrally by two independent, blinded, 66 
pathologists. Analysis was by intention-to-treat. The trial was registered with 67 
ClinicalTrials.gov;NCT01237119. 68 
 69 
Findings: Between 1st August 2010 and 31st May 2013, 26 patients were randomly 70 
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assigned to receive liraglutide and 26 to placebo. 45 (87%) of 52 patients underwent 71 
end-of-treatment liver biopsy at 48 weeks. The primary end-point was met as 9/23 72 
(39%) patients on liraglutide had resolution of definite NASH. This was higher than 73 
the 2 (9%) of 22 responders on placebo (relative risk for all patients that had end-of-74 
treatment biopsy; 4.30, 95% CI 1.04 to 17.74; p=0.019). Fewer patients on liraglutide 75 
(2/23; 9%) demonstrated progression of fibrosis compared to placebo (8/22; 36%) 76 
(p=0.03).  77 
 78 
Interpretation: Liraglutide was safe, well-tolerated and led to histological resolution 79 
of non-alcoholic steatohepatitis, warranting extensive longer-term studies. 80 
 81 
Funding: Wellcome Trust, National Institute of Health Research, Novo Nordisk Ltd. 82 
 83 
Key words: Glucagon-like peptide 1, liraglutide, incretin mimetic, non-alcoholic fatty 84 
liver, non-alcoholic steatohepatitis, liver biopsy 85 
86 
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Introduction 87 
 88 
Non-alcoholic steatohepatitis (NASH) is now the commonest cause of liver disease 89 
and is predicted to be the main indication for liver transplantation by 2020.1 Patients 90 
with NASH have an increased risk of liver and cardiovascular disease (CVD) related 91 
morbidity and mortality,2 compared to those with non-alcoholic fatty liver (NAFL) 92 
and the general population.3, 4 Moreover, there are currently no licensed therapies 93 
for NASH.  94 
 95 
Lifestyle modifications are the mainstay of treatment for NASH,5 yet most patients 96 
fail to achieve, or maintain, dietary goals and weight loss.6 In the two largest 97 
randomised controlled trials in patients with NASH thus far treatment with 98 
pioglitazone, vitamin E (PIVENS)7 and obeticholic acid (FLINT)8 were associated with 99 
improvements in liver histology compared to placebo, with the findings of the 100 
PIVENS trial relevant to patients without type 2 diabetes. Concerns about the side-101 
effects and long-term safety profile of both pioglitazone and Vitamin E has reduced 102 
enthusiasm for their use.9 Obeticholic acid also reduced liver fibrosis in the FLINT 103 
trial and was associated with an elevated LDL cholesterol, which will be studied 104 
further in phase 3.8 105 
  106 
The strong association of NASH with the metabolic syndrome, in particular obesity 107 
and type 2 diabetes, provides a compelling rationale for investigating therapies such 108 
as the gut-derived incretin hormone, glucagon-like peptide-1 (GLP-1), that induce 109 
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weight loss and insulin sensitivity. Native GLP-1 has a potent blood glucose-lowering 110 
action, mediated via its ability to induce insulin secretion and reduce glucagon 111 
secretion in a glucose-dependent manner, as well as suppressing appetite and 112 
delaying gastric emptying.10 Endogenous GLP-1 is degraded within minutes in vivo by 113 
the enzyme dipeptidyl peptidase-4, whereas liraglutide is a long-acting (half-life 13 114 
hours) human GLP-1 analogue.11 Liraglutide has been shown to cause weight loss,12 115 
decrease glycated haemoglobin (HbA1c) and systolic blood pressure and improve 116 
beta-cell function,13 and is licensed for glycaemic control in patients with type 2 117 
diabetes. 118 
 119 
GLP-1 analogues have been shown to reduce liver enzymes and oxidative stress as 120 
well as improving liver histology14 in murine models of NASH.15-17 This may reflect 121 
their effects on obesity and systemic insulin resistance, although studies have also 122 
reported that GLP-1 analogues can act directly on human hepatocytes in vitro, to 123 
reduce steatosis by decreasing de novo lipogenesis and increasing fatty acid 124 
oxidation.15, 18, 19 125 
 126 
To date, human studies investigating the effect of GLP-1 analogues on liver injury 127 
have been limited to case reports,20, 21 a case series (n=8)22 and retrospective studies 128 
of liver enzymes in patients with type 2 diabetes.23,24 However, these studies were 129 
retrospective and lacked histological data, therefore we designed and conducted a 130 
multi-centre randomised controlled trial of liraglutide to test its safety and efficacy in 131 
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the treatment of histologically confirmed NASH in overweight patients with and 132 
without diabetes.  133 
 134 
 135 
  136 
 137 
  138 
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Methods 139 
 140 
Study Design: 141 
The Liraglutide Efficacy and Action in NASH (LEAN) trial was a multicentre, double-142 
blinded, randomised, placebo-controlled trial of 48 weeks treatment with the once 143 
daily (OD) human GLP-1 analogue, liraglutide, in patients with biopsy-proven NASH.  144 
Between 1st August 2010 and 31st May 2013, patients were recruited from 4 trial 145 
centres at hospitals in the United Kingdom (UK). The National Research Ethics 146 
Service (NRES) East Midlands–Northampton committee (UK) and the Medicines and 147 
Healthcare products Regulatory Agency (MHRA) approved all versions of the study 148 
protocol. In addition, all recruitment sites obtained approval from their local hospital 149 
Research and Development (R&D) departments. The University of Birmingham 150 
(Birmingham, UK) acted as the sponsor of the trial. A detailed version of the LEAN 151 
protocol is published online.25 152 
 153 
Participants: 154 
All patients provided written informed consent. The trial entry criteria were based 155 
on a diagnosis of ‘definite’ NASH on liver biopsy obtained within 6 months of 156 
screening. Prior to randomisation, two independent liver histopathologists (SGH, RB) 157 
reviewed all of the liver biopsies to confirm whether a diagnosis of ‘definite’ NASH 158 
was present, as defined by macrovesicular steatosis (>5%), hepatocyte ballooning 159 
(with confirmation of the presence of Mallory’s Hyaline by ubiquitin 160 
immunohistochemistry as necessary) and lobular inflammation (mixed infiltrate, 161 
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related to foci of ballooning).26 In the event of disagreement with regards to a 162 
diagnosis of ‘definite’ NASH, a combined assessment was undertaken to achieve 163 
consensus. All participants had to be 18-70 years old and have a body mass index 164 
(BMI) ≥25 kg/m2 at screening. Patients with type 2 diabetes had to have stable 165 
glycaemic control (HbA1c <9.0%) and be managed by either diet and/or a stable 166 
dose of metformin/sulphonylurea.  167 
 168 
Patients were excluded on the basis of: a history of significant alcohol consumption 169 
(>20 g/day for women or >30 g/day for men), poor glycaemic control (HbA1c > 170 
9.0%), Child-Pugh B/C cirrhosis, other causes of liver disease, confounding 171 
concomitant medications (including insulin, incretin mimetics, thiazolidinediones, 172 
vitamin E) and medical conditions including a history of pancreatitis and 173 
pancreatic/thyroid carcinoma [Supplementary Methods]. 174 
 175 
Randomisation and blinding: 176 
Patients who satisfied the eligibility criteria were randomly assigned (1:1) to 48 177 
weeks treatment with subcutaneous injections of 1.8 mg liraglutide OD (Victoza; 178 
Novo Nordisk A/S, Denmark) or liraglutide-placebo (control; Novo Nordisk A/S, 179 
Denmark) using a computer generated, centrally administered procedure at the 180 
clinical trials unit (Birmingham). Randomisation was based on a minimisation 181 
algorithm and stratified by trial site and diabetes status. To improve gastro-intestinal 182 
tolerability patients underwent a 14-day dose titration, increasing their dose by 0.6 183 
mg every 7 days from a starting dose of 0.6mg OD until the maximum dose of 1.8 mg 184 
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OD was achieved. Patients, investigators, clinical trial site staff and pathologists were 185 
blinded to treatment assignment throughout the study.  186 
 187 
Procedures: 188 
After randomisation, patients returned for study visits at weeks 4, 12, 24, 36 and 48 189 
(end of treatment), at which time the primary outcome was assessed. The end of 190 
study was at week 60, 12 weeks after treatment finished. The schedule for the study 191 
visits and data collection is summarised in the Appendix (Supplementary 192 
methods/Table 1). All patients received standard National Health Services (NHS) care 193 
recommendations on life-style modifications, including exercise, weight reduction 194 
and dietary modification. Patients were not allowed any new prescriptions or over-195 
the-counter therapies that may impact on NASH throughout the duration of the 196 
trial.25 No dose reductions of liraglutide or placebo were allowed throughout the 48-197 
week treatment period. Previous treatment with oral anti-diabetic drugs (metformin 198 
and/or sulphonylurea) was continued at the same dose in participants with type 2 199 
diabetes at randomisation. 200 
 201 
Two independent liver histopathologists (SGH, RB) assessed all baseline and end of 202 
treatment liver biopsies to: (i) determine a diagnosis of ‘definite NASH,’ ‘uncertain 203 
NASH,’ or ‘not NASH’, (ii) to assess the severity of liver disease including the NAFLD 204 
activity score and fibrosis stage. The histopathologists were blinded to study 205 
treatment allocation and clinical/laboratory information. Cases where there was 206 
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disagreement on the presence/absence of definite NASH were reviewed and  207 
consensus reached. For each case consensus was reached for the fibrosis score. 208 
 209 
Outcomes: 210 
The primary outcome measure was assessed using an intention-to-treat analysis of 211 
the proportion of evaluable patients achieving an improvement in liver histology 212 
between liver biopsies at baseline and after 48 weeks of treatment. Histological 213 
improvement was defined as a combination of the disappearance of steatohepatitis 214 
(disappearance of hepatocyte ballooning) and no worsening in fibrosis (defined as an 215 
increase by one stage of the Kleiner Fibrosis classification27). Secondary histological 216 
outcomes included changes in the overall NAS, individual components of NAS 217 
(steatosis, hepatocyte ballooning, lobular inflammation) and the Kleiner fibrosis 218 
stage.27 Fibrosis stages 1a, 1b and 1c were considered as stage 1 for the purposes of 219 
analysis. Other secondary outcome measures included changes from baseline to 48 220 
weeks in serum liver enzymes, non-invasive hepatic biomarkers (CK-18, ELF test), 221 
fasting lipids, glycaemic control (glucose, HbA1c), insulin resistance (HOMA-IR, 222 
ADIPO-IR), anthropometric measures (body weight, BMI, waist circumference), 223 
health-related quality of life scores (SF36v2 physical and mental components) and 224 
dietary consumption per day. 225 
 226 
Statistical analysis 227 
The primary aim of the study was to assess whether the efficacy and safety profile of 228 
liraglutide was worthy of further investigation. Recruiting patients into a no 229 
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treatment placebo-control group provided simultaneous unbiased assessment of 230 
comparable patient groups. Based on other pharmaceutical trials in biopsy-proven 231 
NASH, it was assumed that up to 20% of patients undergoing current standard of 232 
care (placebo) would have an improvement in NASH by week 48. To justify further 233 
investigation of liraglutide treatment, a clinically relevant improvement in liver 234 
histology was considered to be 50% of patients. The sample size was calculated using 235 
A'Hern's single stage phase II methodology, with a one-sided significance level of 236 
0.05 (type 1 error) and power of 90% (type II error 0.10). The design required 21 237 
evaluable patients in the treatment group. To account for withdrawal, the 238 
recruitment target was inflated from 21 to 25 patients per treatment group.25 239 
 240 
All evaluable patients were analysed on an intention-to-treat basis. Evaluable 241 
patients were defined as those who underwent an end-of-treatment biopsy (week 242 
48). Patients were categorised as either achieving the primary histological outcome 243 
(resolution of NASH) or not in each treatment group. The study A’Herns design 244 
stipulated that 8 or more evaluable patients out of 21 (38%) in the liraglutide group 245 
had to achieve histological improvement to be deemed worthy of further 246 
investigation.25  247 
 248 
An unpowered pre-planned secondary analysis of the primary outcome measure was 249 
performed using the chi-squared test to test for a difference between the 250 
proportions of patients with histological improvement in each treatment group. In 251 
addition, a sensitivity analysis was performed for the primary outcome measure, in 252 
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which patients that did not have an end-of-treatment liver biopsy were classified as 253 
‘no histological improvement’ and included in the analysis. A post hoc logistic 254 
regression analysis was undertaken to determine the treatment effect when 255 
adjusted for the stratification variables of trial site and type 2 diabetes, stage of liver 256 
fibrosis as well as weight and glycaemic change during the trial.  257 
  258 
Adjusted relative risks were determined using the Mantel-Haenszel test for diabetes 259 
and fibrosis. Continuous secondary outcome measures were compared between 260 
treatment groups using linear regression, adjusting for parameter baseline values 261 
and allocated treatment (as model covariates, equivalent to ANCOVA). Multilevel 262 
modelling for key continuous outcome measures was undertaken to account for 263 
repeated measures within each patient. Categorical secondary outcomes were 264 
compared between treatment groups using chi-squared tests or Fisher’s exact test 265 
where appropriate. Statistical analyses were performed using Stata Statistical 266 
Software: Release 12. College Station, TX: StataCorp LP.  267 
 268 
Compliance with the trial protocol and safety profile of liraglutide was reviewed on 269 
an annual basis by an independent DMC (appendix), and no concerns were raised. 270 
The trial was registered with ClinicalTrials.gov (NCT01237119). 271 
 272 
Role of the funding source 273 
The LEAN trial represents independent academic research funded by the Wellcome 274 
Trust, Novo Nordisk Ltd and the NIHR Birmingham Liver BRU. The funders of the 275 
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LEAN trial had no role in study design, data collection, data analysis, data 276 
interpretation, or writing of the report. The corresponding author had access to all 277 
data in the study and had final responsibility for the decision to submit for 278 
publication. 279 
  280 
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Results: 281 
 282 
52 patients with histologically confirmed ‘definite’ NASH on central pathology review 283 
were randomly assigned to receive liraglutide (n=26) or placebo (n=26), between 1st 284 
August 2010 and 31st May 2013 [Figure 1]. Participants were recruited from UK sites 285 
as follows: Birmingham (n=31), Nottingham (n=12), Hull (n=6) and Leeds (n=3). With 286 
the exception of one patient randomised to placebo, all patients received their 287 
assigned treatment. Equal numbers of patients missed end of treatment (48-week) 288 
biopsies (n=3) and withdrew from treatment (n=5) in each group. Baseline 289 
demographic, clinical, laboratory and histological features were similar in the two 290 
groups [Table 1]. Mean NAS was 4.9 (SD 0.9) and ranged from 3.0 to 6.5. Of 52 291 
patients, stage 3 fibrosis was present in 21 (40%) and cirrhosis in 6 (12%) on central 292 
review.  293 
 294 
45 (87%) patients had paired (baseline, 48-week) liver biopsies, received treatment 295 
and were included in the intention-to-treat analysis of the primary outcome.  The 296 
primary outcome (8 out of 21 successes (38%) for the single arm analysis) was met, 297 
as 9 (39%) out of 23 patients in the liraglutide group had resolution of definite NASH 298 
with no worsening of fibrosis [Table 2]. The alpha and power associated with 9 out of 299 
23 successes under the same design conditions are 0.027 and 89.5% respectively.  300 
 301 
2 (9%) out of 22 patients on placebo had histological improvement (relative risk 4.30, 302 
95% CI 1.04 to 17.74; Chi-squared test of proportions (9/23 vs 2/22) p=0.019). A pre-303 
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defined sensitivity analysis of the primary outcome measure, in which patients with 304 
a missing end-of-treatment liver biopsy were defined as non-responders, 305 
demonstrated that 9 out of 26 (35%) on liraglutide versus 2 out of 26 (7.7%) on 306 
placebo achieved the primary outcome. This equated to patients on liraglutide 307 
(versus placebo) having a relative risk of 4.5 (95% CI 1.1, 18.9; Chi-squared test, 308 
p=0.017) of achieving the primary outcome. The odds ratio for the treatment effect 309 
resulting from a logistic regression analysis adjusting for the stratification factors of 310 
diabetes status and trial site is 7.83 (95%CI; 1.31, 46.68, p=0.024). No additional 311 
analyses were performed to account for missing data as low absolute numbers of 312 
dropout were observed.   313 
 314 
Similar proportions of patients with [3 out of 8 [38%)] and without [6 out of 15 315 
(40%)] type 2 diabetes achieved the primary outcome with liraglutide treatment. 316 
Both patients assigned to placebo that achieved histological improvement did not 317 
have type 2 diabetes at baseline. The relative risk for non-diabetic patients achieving 318 
the primary end-point was 3.4 (95% CI 0.8, 14.4; p=0.11) for liraglutide versus 319 
placebo. As there were no patients with diabetes that responded in the placebo arm 320 
a factor of 0.5 was added to all 4 values in the contingency table for diabetic 321 
patients. Using this adjustment the relative risk for diabetic patients was calculated 322 
as 4.7 (95% CI 0.3, 75.0; p=0.20). There was no evidence of heterogeneity (p=0.841). 323 
The relative risk of response on liraglutide compared to placebo adjusted for 324 
diabetes using the stratified Mantel-Haenszel test was 3.7 (95% CI 1.0, 13.5; 325 
p=0.047).  326 
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 327 
Fewer patients on liraglutide (2 of 23; 9%) demonstrated progression of fibrosis 328 
compared to placebo (8 of 22; 36%); relative risk 0.2 (95% CI 0.1, 1.0); Fisher’s exact 329 
test, p=0.04). A greater proportion of patients on liraglutide had improvements in 330 
steatosis (relative risk 1.8 (95% CI 1.1, 3.0); Chi-squared p=0.01) and hepatocyte 331 
ballooning (relative risk 1.9 (95% CI 1.0, 3.8); Chi-squared p=0.05) compared to 332 
placebo and no differences were seen in lobular inflammation (relative risk 0.9 (95% 333 
CI 0.5, 1.6); Chi-squared p=0.65) and overall NAS (relative risk 1.2 (95% CI 0.8, 1.7); 334 
Chi squared p=0.46) [Table 2].  335 
 336 
Differences at 48 weeks in serum aminotransferases with liraglutide were not 337 
significant compared to placebo, with only serum gamma-glutamyl transferase 338 
reaching significance [Figure 2; Table 3]. However, multilevel modelling 339 
(Supplementary Results) of longitudinal parameters indicated significant differences 340 
in both alanine aminotransferase and gamma glutamyltransferase between the two 341 
treatment arms thereby supporting the changes over time illustrated in Figure 2. 342 
There were also trends in the reduction of serum biomarkers of hepatocyte injury 343 
(serum CK-18; p=0.097) and fibrosis (serum ELF; p=0.05) with liraglutide compared to 344 
placebo. 345 
 346 
Compared with placebo, 48 weeks treatment with liraglutide was associated with 347 
significant reductions in body weight and body mass index (Table 3). Most of the 348 
beneficial effects of liraglutide on weight were achieved by 12 weeks treatment and 349 
17 
 
sustained throughout treatment [Figure 2]. Patients assigned to liraglutide also had 350 
significant improvements in HbA1c compared to placebo. Improvements in weight 351 
and HbA1c were confirmed by multilevel modelling (Supplementary Table 5). 352 
Notably, weight increased and metabolic changes reverted towards baseline 12 353 
weeks after liraglutide was discontinued [Figure 2; Supplementary Table 2].  There 354 
was no significant difference in HDL or systolic blood pressure when assessed using 355 
multilevel modelling. 356 
 357 
Post hoc analysis was undertaken to determine the clinical/laboratory changes that 358 
occurred in patients that had resolution of NASH with liraglutide treatment (n=9; 359 
‘responder’) compared to those that did not (n=14; ‘non-responder’) 360 
(Supplementary Table 7). Changes in weight and glycaemic control (HbA1c) in 361 
patients on liraglutide were not significantly different for responders and non-362 
responders (Figure 3a/b). 363 
 364 
Patients on liraglutide reported significant improvements in the physical component 365 
score of the SF36vs questionnaire compared to those on placebo (4.05 (95% CI; 0.20, 366 
7.90; p=0.04).  367 
 368 
The majority of AEs were grade 1 (mild) to grade 2 (moderate) in severity, transient 369 
and similar in the two treatment groups for all organ classes and symptoms, with the 370 
exception of gastrointestinal disorders (Table 4). Patients on liraglutide were prone 371 
to diarrhoea (42% versus 19%), constipation (23% versus 0%) and loss of appetite 372 
18 
 
(31% versus 8%) compared to those on placebo. Patients with advanced fibrosis (F3-373 
4) had similar rates of AE to those with milder grades of fibrosis (Supplementary 374 
Table 9). Two (8%) patients in the liraglutide group withdrew from treatment due to 375 
nausea and diarrhoea, but still underwent liver biopsy at week 48. A further three 376 
treatment withdrawals in the liraglutide group were due to needle phobia, work 377 
commitments and loss to follow-up and withdrew their consent from the study and 378 
did not undergo end-of-treatment liver biopsy.  379 
 380 
There were two serious AEs in the liraglutide group (tuberculosis, migraines) both of 381 
which were judged to be unrelated to therapy. There were no deaths nor cases of 382 
pancreatitis, hepatitis or liver failure during the trial. No patients developed 383 
antibodies against liraglutide on testing at week 60. Post hoc analysis highlighted 384 
that the numbers of AEs were similar between patients with and without advanced 385 
fibrosis (F3-F4) (Supplementary Table 9). 386 
 387 
 388 
 389 
 390 
  391 
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Discussion 392 
 393 
In this double-blind, randomised, placebo-controlled phase II trial, the long-acting 394 
GLP-1 analogue, liraglutide, met the pre-defined primary end-point and led to 395 
resolution of NASH. Moreover, improvements in weight and glycaemic control with 396 
liraglutide may have a favourable effect on the future risk of CVD and premature 397 
death in patients with NASH, although longer term outcome studies are needed to 398 
confirm this. Study withdrawal (i.e. no end-of-treatment biopsy) rates were the same 399 
in both treatment groups and had no impact on the primary end-point. Liraglutide 400 
was safe and well-tolerated, irrespective of the severity of underlying disease. 401 
 402 
This study has a number of strengths. Firstly, this is the first randomised, placebo-403 
controlled trial to report the effect of a GLP-1 analogue on liver histology in patients 404 
with NASH. Secondly, the study population included patients with and without type 405 
2 diabetes and liver cirrhosis. Thirdly, in light of the documented intra- and inter 406 
variability in assessment of liver biopsies27 we had two independent, blinded, central 407 
assessments of liver biopsies at baseline (same sections used for eligibility and 408 
impact of treatment) and at end of treatment. This avoided inclusion of patients 409 
without definite NASH, as happened in 21% and 20% of patients in PIVENS7 and 410 
FLINT8 trials, respectively. Fourthly, we collated detailed recording of concomitant 411 
medications (i.e. lipid-lowering and anti-diabetic medications) and dietary intake (i.e. 412 
caffeine, vitamin E, alcohol) for the duration of the trial. 413 
 414 
Our sample size was similar to previous proof-of concept studies 28, albeit smaller 415 
20 
 
than some later stage phase 2 studies 7, 8, and patients were extensively phenotyped 416 
and well-matched for features of the metabolic syndrome with the exception of BMI. 417 
The study was appropriately powered for a hard histological end-point, and the level 418 
of histological resolution of NASH with liraglutide (9 of 23; 39%) was comparable to 419 
that previously reported with vitamin E (29 of 80; 36%), pioglitazone (33 of 70; 47%)7 420 
and obeticholic acid (22 of 102; 22%).8 The reported placebo rate (9%) was slightly 421 
lower than those previously described (13-21%),7, 8 but this is likely because in this 422 
study clearance of NASH had to be accompanied without any worsening of fibrosis 423 
(which has not been previously adopted). 424 
 425 
Although liraglutide met the primary end-point, it did not result in significant mean 426 
changes in the composite NAS score, as reported with pioglitazone, vitamin E and 427 
obeticholic acid.7, 8 Notably, a greater proportion of patients on liraglutide had 428 
improvements in steatosis and hepatocyte ballooning indicating that the overall 429 
pattern of changes are in keeping with a reduction in histological damage with 430 
liraglutide. With the exception of lobular inflammation, a greater proportion of 431 
patients on liraglutide improved steatosis (83% versus 45%; p=0.009) and hepatocyte 432 
ballooning (61% versus 32%; p=0.05), which would suggest that a larger study could 433 
identify significant mean changes in NAS. Liraglutide also showed evidence of 434 
efficacy in a post hoc analysis using the primary end-points (which utilised NAS) that 435 
were in place for the FLINT and PIVENS trials (Supplementary Table 6).    436 
 437 
Resolution of NASH was selected as the primary end-point instead of changes in 438 
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NAS, in keeping with guidance from an expert consortium.26 Notably, NAS score does 439 
not predict liver-related morbidity or mortality, whereas the presence of NASH 440 
(versus simple NAFL) is associated with a significant increase in liver-related 441 
outcomes and all-cause mortality.3, 4  442 
 443 
Recent data have identified the importance of liver fibrosis as being the key 444 
determinant of clinical outcomes in patients with NASH.29 Despite the relatively 445 
short duration of this trial fewer patients on liraglutide had progression of fibrosis 446 
(p=0.04) and there was also a greater reduction in serum ELF levels (p=0.05) than 447 
placebo. Whilst there was no difference in mean change in fibrosis stage (p=0.18) 448 
between the two groups this is likely a reflection of the duration of treatment, and a 449 
longer course should be evaluated. Notably, the univariate analysis suggested that 450 
patients with more severe fibrosis (F3/F4) at baseline were less likely to respond to 451 
liraglutide, although liraglutide still had a positive treatment effect after adjusting for 452 
baseline fibrosis (Supplementary Table 4).  453 
 454 
The clearance of NASH by liraglutide is likely to be multi-factorial and a consequence 455 
of its cumulative effect on weight loss and glycaemic control. Comparison of patients 456 
with and without histological response to liraglutide, albeit limited by small 457 
numbers, demonstrates a possible continued modest reduction in weight loss in 458 
responders. Post hoc logistic regression (Supplementary Table 5) indicates that the 459 
effects of liraglutide are likely to be due to a combination of a direct hepatic effect 460 
(odds ratio for treatment effect adjusted for weight was 4.12 (CI 0.66-25.8; p=0.131)) 461 
22 
 
and an effect on weight loss. This would imply that the mechanism of action of GLP-1 462 
analogues in NASH is not solely explained by improvements in weight and metabolic 463 
phenotype, and indeed in vitro studies have shown that GLP-1 analogues improve 464 
the ability of the hepatocyte to handle excess NEFA and lipid production by 465 
modulating lipid transport, beta-oxidation, and de novo lipogenesis,16, 18, 30 all of 466 
which have been implicated in the pathogenesis of NASH. These observations have 467 
been confirmed in liraglutide-treated mice, in which reductions in hepatic steatosis, 468 
insulin resistance (via clamp technique) and endoplasmic reticulum oxidative stress 469 
occurred in the absence of weight loss16, 31. When this study was designed liraglutide 470 
was only available at the 1.8mg dose, and since then a higher dose (3.0mg) has been  471 
approved for weight management12. It is possible that a higher dose of liraglutide 472 
could provide greater efficacy in the setting of NASH, although the level of added 473 
benefit is unclear. 474 
 475 
Currently, safety data regarding the use of GLP-1 analogues in liver disease are 476 
limited to solitary case reports20, 21 and retrospective analysis of large cohorts of 477 
patients with type 2 diabetes and elevated transaminases.23, 24 Liraglutide was 478 
generally well tolerated in the study and had a similar AE profile to placebo, with the 479 
exception of predictable gastrointestinal symptoms (mainly diarrhoea, constipation 480 
and loss of appetite). These, however, were mainly transient and mild-to-moderate 481 
in severity.  482 
 483 
At present, there is a significant unmet need of therapies in patients with NASH 484 
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cirrhosis. We, therefore, elected to include patients with cirrhosis in this study to 485 
pilot the efficacy, but importantly highlight the safety of liraglutide in this setting. 486 
Due to the fact that cirrhosis is the final stage of the Kleiner scoring system (e.g. 4/4), 487 
these patients may have been advantaged in achieving the primary end-point, as by 488 
definition they could not have ‘worsening of fibrosis’. However, their inclusion did 489 
not inflate the histological response in the liraglutide group, as only one patient with 490 
cirrhosis met the primary end-point and they received placebo. 491 
 492 
In conclusion, the unique combination of histological efficacy and improvement of 493 
the metabolic syndrome with liraglutide render it an attractive therapy for patients 494 
with NASH and warrant further investigation in larger studies. 495 
  496 
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Panel: Research in context 497 
Evidence before this study 498 
Non-alcoholic steatohepatitis (NASH) is now the commonest cause of chronic liver 499 
disease and incurs a significantly increased risk of both liver- and cardiovascular 500 
disease (CVD)-related morbidity and mortality.2, 4 Despite this, there are no licensed 501 
therapies for NASH.5 To date, clinical trials of pioglitazone, vitamin E (PIVENS)7 and 502 
obeticholic acid in patients with biopsy-proven NASH (FLINT)8 have shown 503 
improvements in liver histology compared to placebo. With the exception of FLINT, 504 
these trials have excluded patients with type 2 diabetes, thus their effects in patients 505 
with diabetes are unknown. Moreover, there remain concerns about the side-effects 506 
and long-term safety of pioglitazone and Vitamin E which has reduced enthusiasm 507 
for their use.  508 
 509 
In 2009, the long-acting glucagon-like peptide-1 (GLP-1) analogue, liraglutide, was 510 
licensed for glycaemic control in overweight patients with type 2 diabetes. 511 
Liraglutide also suppresses appetite centrally and delays gastric emptying10 which 512 
induces weight loss12, 13 rendering it an attractive therapeutic option for NASH. Prior 513 
to designing the LEAN trial, the published literature were reviewed by searching 514 
PubMed, between 1st January 1965 and 31st December 2009, for [‘NAFLD’, ‘NASH’, 515 
‘fatty liver’, ‘steatohepatitis’ or ‘liver injury] and [‘glucagon-like peptide 1’, ‘GLP-1’, 516 
‘liraglutide’, ‘exenatide’ or ‘incretin’]. GLP-1 analogues, including liraglutide, 517 
improved liver enzymes, oxidative stress and hepatic steatosis in murine models in 518 
vivo and in isolated in vitro murine and human hepatocyte studies.15, 16, 18, 19, 30, 31 519 
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Human studies investigating the effect on liver injury were limited to single case 520 
reports,20, 21 and large retrospective studies of liver enzymes in patients with type 2 521 
diabetes.23 An individual patient level meta-analysis of over 4000 patients with type 522 
2 diabetes was performed, comparing 26 weeks of treatment with liraglutide to 523 
placebo. Liraglutide significantly improved liver enzymes in a dose-dependent 524 
manner, with comparable safety profiles in those patients with and without 525 
abnormal liver biochemistry.24 These findings formed the basis for this phase II 526 
randomised, placebo-controlled trial of liraglutide for NASH. Despite extending the 527 
literature search dates to 1st April 2015, no clinical trials of GLP-1 based therapies in 528 
NASH were identified.  529 
 530 
Added value of this study 531 
This study is a first in class, randomised, controlled trial of GLP-1 analogue in patients 532 
with NASH. Liraglutide met the primary end-point of histological resolution of NASH 533 
with no worsening in fibrosis. In addition to improvements in histological steatosis 534 
and hepatocyte ballooning, fewer patients on liraglutide had progression of fibrosis. 535 
Uniquely for tested therapies in NASH, liraglutide improved several key components 536 
of the metabolic syndrome, including weight and glycaemic control, which is 537 
important, as cardiovascular disease accounts for the majority of deaths in cohorts 538 
of patients with NASH.   539 
 540 
 541 
 542 
26 
 
Implications of all the available evidence 543 
Due to the growing global burden of NASH and the lack of licensed therapies there is 544 
a pressing need for effective interventions. Given the associated cardiovascular 545 
morbidity and mortality with NASH, the use of therapies such as liraglutide which 546 
improve both liver histology and many aspects of the metabolic syndrome are 547 
needed to improve outcomes for patients with NASH. Future, longer-term studies 548 
with liraglutide are needed to confirm their efficacy in patients with NASH, as well as 549 
to establish their cardiovascular benefits. 550 
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Figures legends: 600 
Figure 1 Trial profile: *One (1.9%) patient that was assigned to placebo never 601 
received treatment, as they disclosed use of an ineligible medication (Dipetidyl 602 
peptidase-IV inhibitor) 24 hours post-randomisation.** Two patients randomised to 603 
liraglutide withdrew from treatment (2, 16 weeks) due to adverse gastrointestinal 604 
events, but still proceeded with the 48 week liver biopsy. One patient randomised to 605 
placebo withdrew from treatment due to reactive hypoglycaemia (36 weeks) but still 606 
proceeded with the 48 week liver biopsy. 607 
 608 
Figure 2. Changes from baseline in metabolic parameters and liver enzymes 609 
according to treatment group. Mean values (95% CI, error bars) of change from 610 
baseline during treatment with liraglutide (blue line) or placebo (red line) for up to 611 
48 weeks followed by a 12 week post-treatment period are shown (broken line). (A) 612 
Weight, (B) HbA1c and (D) Alanine aminotransferase decreased during treatment 613 
with liraglutide with a rebound back toward baseline after discontinuation. (C) 614 
Serum γ-glutamyl transpeptidase concentrations decreased with liraglutide 615 
treatment. There was no difference in (E) HDL cholesterol and (F) systolic BP over 616 
time between liraglutide and placebo. 617 
 618 
Figure 3. Changes from baseline in weight [a] and HbA1c [b] for patients with and 619 
without a histological response to liraglutide treatment. Median values (IQR, error 620 
bars) of changes from baseline in patients with histological improvement (responder; 621 
blue line) and no histological improvement (non-responders; red line) on liraglutide 622 
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treatment for 48 weeks and post treatment follow-up (broken line) at 60 weeks. 623 
Mean changes at 48 weeks and associated p-values are reported in Supplementary 624 
Table  7.   625 
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